Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.
Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.
复制标题
DOI：
10.1093/rheumatology/keac574
复制
发表时间：
2023-06-01
期刊：
影响因子：
5.5
通讯作者：
Fairclough, Lucy
中科院分区：
文献类型：
--
作者：
Gumber, Leher;Gomez, Nancy;Hopkins, Georgina;Tucis, Davis;Bartlett, Laura;Ayling, Kieran;Vedhara, Kavita;Steers, Graham;Chakravorty, Mithun;Rutter, Megan;Jackson, Hannah;Tighe, Patrick;Ferraro, Alastair;Power, Sheila;Pradere, Marie-Josephe;Onion, David;Lanyon, Peter C.;Pearce, Fiona A.;Fairclough, Lucy
2019 冠状病毒疫苗对罕见自身免疫性风湿病 (RAIRD) 的反应仍知之甚少；特别是人们对于人们是否会产生有效的 T 细胞反应知之甚少。我们进行了一项观察性研究，旨在评估 RAIRD 患者与健康对照 (HC) 相比，在第二次严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗接种后的短期体液和细胞介导的 T 细胞反应。第二次给药后收集血样，测量抗尖峰、抗核衣壳抗体水平和 SARS-CoV-2 特异性 T 细胞反应，并与 HC 进行比较。激活诱导标记和深度表型分析用于识别高抗体组和无/低抗体组之间 T 细胞的差异，然后进行多维聚类。总共纳入了 50 名 RAIRD 患者（31 名患有 AAV，4 名患有其他系统性血管炎，9 名患有 SLE，6 名患有肌炎）。与 HC 相比，RAIRD 患者的中位抗尖峰水平显着较低 (P<0.0001)。 15 名 (33%) 患者的水平无法检测到，26 名 (57%) 患者的水平低于最低 HC。与较长的疫苗接种前时期相比，过去 12 个月的利妥昔单抗 (P= 0.003) 与免疫原性降低相关。无/低抗体组与高抗体组之间的 B 细胞百分比 (P = 0.03) 和刺突特异性 CD4+ T 细胞 (P = 0.02) 存在显着差异。无/低抗体组患者的终末分化（耗尽）T 细胞百分比较高。两次给药后，大多数 RAIRD 患者的抗体水平低于最低的 HC 和较低的抗尖峰 T 细胞。无抗体/低抗体的 RAIRD 患者的记忆 T 细胞数量减少且质量较差，缺乏增殖和功能能力。
Coronavirus 2019 vaccine responses in rare autoimmune rheumatic diseases (RAIRDs) remain poorly understood; in particular there is little known about whether people develop effective T cell responses. We conducted an observational study to evaluate the short-term humoral and cell-mediated T cell response after the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in RAIRD patients compared with healthy controls (HCs). Blood samples were collected after the second dose and anti-spike, anti-nucleocapsid antibody levels and SARS-CoV-2-specific T cell responses were measured and compared with those of HCs. Activation-induced marker and deep phenotyping assays were used to identify differences in T cells between high and no/low antibody groups, followed by multidimensional clustering. A total of 50 patients with RAIRDs were included (31 with AAV, 4 with other systemic vasculitis, 9 with SLE and 6 with myositis). The median anti-spike levels were significantly lower in RAIRD patients compared with HCs (P < 0.0001). Fifteen (33%) patients had undetectable levels and 26 (57%) had levels lower than the lowest HC. Rituximab in the last 12 months (P = 0.003) was associated with reduced immunogenicity compared with a longer pre-vaccination period. There was a significant difference in B cell percentages (P = 0.03) and spike-specific CD4+ T cells (P = 0.02) between no/low antibody vs high antibody groups. Patients in the no/low antibody group had a higher percentage of terminally differentiated (exhausted) T cells. Following two doses, most RAIRD patients have lower antibody levels than the lowest HC and lower anti-spike T cells. RAIRD patients with no/low antibodies have diminished numbers and poor quality of memory T cells that lack proliferative and functional capacities.
登录
查看更多内容
影响因子：
27.4
作者：
Mrak, Daniel;Tobudic, Selma;Bonelli, Michael
通讯作者：
Bonelli, Michael
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
20.3
作者：
Shields AM;Venkatachalam S;Paneesha S;Ford M;Sheeran T;Kelly M;Karim F;Qureshi I;Salhan B;DeSilva N;Stones J;Lee S;Khawaja J;Kaudlay PK;Whitmill R;Nabikakepoto G;Faustini SE;Richter AG;Drayson MT;Basu S
通讯作者：
Basu S
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
4.9
作者：
Fischer, Lara;Gerstel, Patricia Francis;Ribi, Camillo
通讯作者：
Ribi, Camillo